Study of the Pathophysiological Mechanisms Involved in Bleeding Events

Inclusion Criteria: * Patient with a clinical syndrome of Lowe (congenital cataracts, renal tubular dysfunction and neuromuscular damage) with a molecular defect in the gene known OCRL1. * For the centre of Necker, patients should have a weight\> 10 kg. For the centre of Toulouse site, patients should have a weight\> 40 kg. * No alteration of glomerular function (creatinine clearance\> 30 ml/min/1.73m ²) * No significant anemia (hematocrit\> 25%, hemoglobin\> 8 g / L) * Every patient should have included a signed informed consent. For minor patients, the consent of parents or legal guardian must be obtained. * Patients may be included only if they receive social security coverage or CMU Exclusion Criteria: * Weight less than 10 kg for the centre of Necker * Weight less than 40 kg for the centre of Toulouse * Major renal insufficiency (creatinine clearance \<30 ml/min/1.73m ²) * Profound anemia (hematocrit \<25%, Hb \<8g/dl) * Patients taking drugs interfering with hemostasis in the eight days before the survey * Patients with major behavior disorder making it difficult to achieve the blood sample, despite the nitrous oxide * Patients with a other pathology of hemostasis (hemophilia, thrombotic disease) * Participation in another clinical study requiring a blood sample within 4 weeks * Contraindication to EMLA patch: confers Summary of Product Characteristics. * Contraindication to KALINOX: confers Summary of Product Characteristics.